Our Corporate M&A and Tax teams advised Sever Life Sciences on its disposal of Nordic Group B.V., a European specialty pharmaceutical platform to Alfasigma.
This transaction marks a significant step in Alfasigma's growth strategy, strengthening its specialty care portfolio and expanding its presence across key European markets according to Alfasigma.
The cross-border transaction involved multiple jurisdictions and reflects the continued consolidation within the European healthcare and pharmaceutical sector.
Our multidisciplinary team provided comprehensive Dutch legal, tax and notarial advice in connection with this transaction. The transaction is subject to customary closing conditions.
Nordic Group B.V. is an international specialty pharmaceutical company headquartered in Hoofddorp, The Netherlands, with a diversified portfolio of branded and niche pharmaceutical products marketed across Europe and selected international markets.